MedApp Valuation
Is MDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of MDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MDA?
Other financial metrics that can be useful for relative valuation.
| What is MDA's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | zł81.29m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 14.4x |
| Enterprise Value/EBITDA | 175.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MDA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.1x | ||
SNT Synektik Spólka Akcyjna | 1.9x | 4.6% | zł1.1b |
BMX BioMaxima | 1.4x | n/a | zł63.9m |
EFE Europejski Fundusz Energii Spólka Akcyjna | 32.6x | n/a | zł5.4m |
CRM PZ Cormay | 0.6x | n/a | zł50.9m |
MDA MedApp | 14.5x | n/a | zł83.3m |
Price to Earnings Ratio vs Industry
How does MDA's PE Ratio compare vs other companies in the European Healthcare Services Industry?
Price to Sales Ratio vs Fair Ratio
What is MDA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 14.2x |
| Fair PS Ratio | n/a |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?